| Quarterly Financials | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
Revenue  | 121 | 184 | 89 | 66 | 71 | 57 | 57 | 70 | 68 | 70 | 79 | 93 | 80 | 90 | 85 | 117 | 112 | 112 | 124 | 158 |
| Expenses | 73 | 100 | 64 | 48 | 52 | 40 | 41 | 74 | 54 | 54 | 61 | 78 | 63 | 70 | 67 | 90 | 87 | 86 | 94 | 118 |
| EBITDA | 49 | 84 | 25 | 18 | 18 | 17 | 16 | -4 | 14 | 16 | 17 | 14 | 18 | 20 | 18 | 27 | 25 | 26 | 30 | 40 |
| Operating Profit % | 40 % | 45 % | 28 % | 25 % | 26 % | 28 % | 27 % | -7 % | 20 % | 22 % | 21 % | 15 % | 22 % | 22 % | 21 % | 22 % | 22 % | 23 % | 24 % | 25 % |
| Depreciation | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 3 |
| Profit Before Tax | 46 | 80 | 22 | 14 | 14 | 12 | 10 | -10 | 7 | 8 | 10 | 6 | 11 | 13 | 11 | 19 | 17 | 19 | 22 | 32 |
| Tax | 11 | 21 | 6 | 4 | 4 | 2 | 3 | -2 | 2 | 2 | 2 | 2 | 3 | 4 | 3 | 5 | 5 | 4 | 6 | 6 |
| Net Profit | 34 | 60 | 16 | 11 | 11 | 9 | 7 | -7 | 5 | 6 | 8 | 4 | 8 | 9 | 9 | 15 | 12 | 14 | 16 | 25 |
| EPS in ₹ | 32.96 | 57.33 | 15.20 | 9.97 | 9.99 | 8.82 | 6.82 | -7.23 | 5.10 | 5.99 | 7.39 | 4.08 | 8.04 | 8.15 | 8.21 | 13.95 | 11.49 | 13.60 | 15.42 | 24.39 |
Kwality Pharmaceuticals
Kwality Pharmaceuticals
2,233.00
+95.60
(4.47%)
Market Cap
2,317.01 Cr
PE Ratio
32.90
Volume
1,08,776.00
Day High - Low
2,319.80 - 2,161.20
52W High-Low
2,210.00 - 1,561.00
Key Fundamentals
Market Cap
2,317.01 Cr
EPS
64.90
PE Ratio
32.90
PB Ratio
6.70
Book Value
318.80
EBITDA
117.41
Dividend Yield
0.00 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
15.17
Debt to Equity
0.43
Actual
Company News
View All News
Kwality Pharmaceuticals outlines its drug development pipeline, including biosimilars and monoclonal antibodies targeting H2 CY27 and H1 CY28 launches, alongside a 50+ product hormone portfolio.
Kwality Pharmaceuticals posts record FY26 revenue of ₹503 crore (+36% YoY) and PAT of ₹67.34 crore (+69% YoY); Q4 FY26 revenue at ₹157.11 crore; EPS at ₹64.90.
Kwalitity Pharmaceuticals Limited submitted its mandatory certificate under SEBI Regulation 74(5) for Q4 FY26, confirming compliance with dematerialization requirements through March 31, 2026.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,840.60 | #1 4,41,621.59 | 40.42 | #1 58,220.10 | 6.38 | #1 11,565 | 25.80 | 54.03 | |
6,756.50 | 1,79,363.85 | 73.73 | 10,560.00 | 8.73 | 2,520 | 13.44 | 57.30 | |
4,572.60 | 1,54,757.56 | 66.80 | 13,753.00 | 19.18 | 2,028 | -26.91 | 66.36 | |
1,413.90 | 1,14,212.11 | 29.26 | 27,711.70 | -2.46 | 3,783 | -55.32 | 64.19 | |
1,331.40 | 1,11,124.37 | 26.24 | 33,593.30 | -0.44 | 3,998 | -86.05 | 57.44 | |
1,072.95 | 1,07,963.88 | 20.40 | 26,719.70 | 13.65 | 5,242 | 7.82 | 73.90 | |
2,287.20 | 1,04,534.93 | #1 19.46 | 27,487.50 | 19.98 | 5,345 | #1 87.72 | 48.15 | |
2,457.50 | 1,01,446.85 | 52.84 | 14,277.60 | 12.03 | 1,750 | 31.75 | 59.66 | |
1,454.60 | 84,483.40 | 24.29 | 33,384.70 | 3.21 | 3,376 | 1.99 | 51.11 | |
1,356.30 | 73,220.75 | 81.46 | 6,812.90 | #1 21.03 | 884 | 21.18 | 78.36 |
Growth Rate
Revenue Growth
35.20 %
Net Income Growth
66.98 %
Cash Flow Change
22.66 %
ROE
42.98 %
ROCE
34.64 %
EBITDA Margin (Avg.)
4.93 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Total Assets | 37 | 51 | 71 | 96 | 105 | 133 | 166 | 341 | 354 | 394 | 447 | 592 |
| Fixed Assets | 13 | 13 | 17 | 20 | 29 | 43 | 57 | 92 | 121 | 139 | 146 | 173 |
| Current Assets | 25 | 38 | 53 | 75 | 75 | 89 | 106 | 228 | 207 | 243 | 284 | 406 |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 12 | 14 | 0 | 0 | 17 |
| Investments | 1 | 2 | 3 | 5 | 4 | 3 | 4 | 0 | 0 | 0 | 0 | 78 |
| Other Assets | 24 | 37 | 51 | 71 | 72 | 87 | 102 | 237 | 219 | 255 | 302 | 0 |
| Total Equity & Liabilities | 37 | 51 | 71 | 96 | 105 | 133 | 166 | 341 | 354 | 394 | 447 | 592 |
| Current Liabilities | 17 | 27 | 42 | 62 | 61 | 68 | 78 | 140 | 126 | 152 | 170 | 226 |
| Non Current Liabilities | 1 | 3 | 4 | 6 | 8 | 20 | 28 | 21 | 29 | 20 | 15 | 37 |
| Total Equity | 19 | 21 | 25 | 29 | 36 | 45 | 60 | 180 | 199 | 223 | 262 | 332 |
| Reserve & Surplus | 15 | 17 | 20 | 19 | 27 | 36 | 51 | 171 | 190 | 214 | 254 | 321 |
| Share Capital | 4 | 5 | 5 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 1 | 0 | 2 | -1 | -0 | 0 | 4 | 3 | -6 | -1 | 10 |
| Investing Activities | -1 | -3 | -7 | -6 | -12 | -18 | -23 | -63 | -48 | -26 | -29 |
| Operating Activities | 1 | -3 | 4 | -1 | 14 | 6 | 27 | 61 | 41 | 43 | 53 |
| Financing Activities | 1 | 6 | 5 | 5 | -2 | 12 | 1 | 6 | 1 | -17 | -14 |
Share Holding
| % Holding | Mar 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
| Promoter | 54.13 % | 54.24 % | 54.24 % | 54.43 % | 54.45 % | 54.45 % | 54.45 % | 54.74 % | 54.74 % | 54.77 % | 54.77 % | 54.83 % | 54.83 % | 54.83 % | 54.83 % | 54.83 % | 54.83 % | 54.83 % | 54.83 % | 54.87 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.50 % | 2.79 % |
| DIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.00 % | 0.00 % | 0.02 % | 0.03 % | 0.32 % | 0.33 % | 0.33 % | 0.33 % | 0.36 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 23.18 % | 25.38 % | 25.91 % | 26.29 % | 26.54 % | 26.25 % | 25.92 % | 26.27 % | 29.29 % | 31.64 % | 32.95 % | 31.70 % | 31.78 % | 32.78 % | 33.25 % | 33.39 % | 33.32 % | 33.68 % | 33.02 % | 31.64 % |
| Others | 22.69 % | 20.38 % | 19.84 % | 19.28 % | 19.01 % | 19.30 % | 19.63 % | 18.99 % | 15.96 % | 13.58 % | 12.27 % | 13.47 % | 13.40 % | 12.38 % | 11.90 % | 11.47 % | 11.52 % | 11.16 % | 11.32 % | 10.35 % |
| No of Share Holders | 148 | 168 | 379 | 581 | 1,049 | 4,198 | 5,376 | 6,211 | 6,943 | 6,291 | 5,786 | 5,695 | 5,273 | 7,487 | 8,947 | 9,420 | 10,115 | 11,595 | 10,709 | 10,555 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 12 Oct 2017 |  Bonus | 1:1 | 11 Oct 2017 | 0.00 | 0.00 |
| 24 Sept 2024 |  Annual General Meeting | NA | 24 Sept 2024 | 783.50 | 808.10 |
| 30 Oct 2024 |  Quarterly Result Announcement | NA | 30 Oct 2024 | 818.30 | 812.35 |
| 31 Jan 2025 | Quarterly Result Announcement | NA | 31 Jan 2025 | 892.20 | 870.20 |
| 19 May 2025 | Quarterly Result Announcement | NA | 19 May 2025 | 719.45 | 809.00 |
| 11 Aug 2025 | Quarterly Result Announcement | NA | 11 Aug 2025 | 1,124.45 | 1,132.65 |
| 09 Sept 2025 | Annual General Meeting | NA | 09 Sept 2025 | 1,069.05 | 946.35 |
| 13 Nov 2025 | Quarterly Result Announcement | NA | 13 Nov 2025 | 898.20 | 881.15 |
| 12 Feb 2026 | Quarterly Result Announcement | NA | 12 Feb 2026 | 1,058.00 | 1,147.50 |
| 19 May 2026 | Quarterly Result Announcement | NA | 19 May 2026 | 1,727.00 | 1,833.80 |
Announcements
Announcement under Regulation 30 (LODR)-Newspaper Publication
3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Earnings Call Transcript3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Investor Presentation6 days ago
6 days agoAudited Financial Results For The Quarter And Year Ended 31St March 2026.6 days ago
6 days agoBoard Meeting Outcome for Audited Financial Results For The Quarter And Year Ended 31St March 20266 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation10 days ago
10 days agoBoard Meeting Intimation for Considering The Standalone & Consolidated Audited Financial Results For The Quarter And Year Ended March 31 2026May 08, 2026
May 08, 2026Announcement under Regulation 30 (LODR)-Credit RatingMay 08, 2026
May 08, 2026Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 30, 2026
Apr 30, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 08, 2026
Apr 08, 2026Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotMar 30, 2026
Mar 30, 2026 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 30, 2026
Mar 30, 2026Closure of Trading WindowMar 26, 2026
Mar 26, 2026Update On Bioequivalence (BE) Program - Successful Completion Of Phase 1 By Kwality Pharmaceuticals Ltd.Mar 10, 2026
Mar 10, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 05, 2026
Mar 05, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 05, 2026
Mar 05, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 27, 2026
Feb 27, 2026Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 26, 2026
Feb 26, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 20, 2026
Feb 20, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 14, 2026
Feb 14, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 14, 2026
Feb 14, 2026Investor Presentation Of Financial Results For The Quarter And Nine Months Ended December 31 2025Feb 12, 2026
Feb 12, 2026Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended 31-12-2025Feb 12, 2026
Feb 12, 2026Board Meeting Outcome for Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2025Feb 12, 2026
Feb 12, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 05, 2026
Feb 05, 2026Announcement under Regulation 30 (LODR)-Change in ManagementFeb 04, 2026
Feb 04, 2026Announcement under Regulation 30 (LODR)-Change in ManagementFeb 02, 2026
Feb 02, 2026Board Meeting Intimation for Consideration And Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended On 31St December 2025.Feb 02, 2026
Feb 02, 2026Board Meeting Outcome for Appointment Of Mr. Bhavesh Mahajan (DIN: 09614108) As Additional Independent Director Of The CompanyJan 28, 2026
Jan 28, 2026Announcement under Regulation 30 (LODR)-Change in ManagementJan 28, 2026
Jan 28, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 14, 2026
Jan 14, 2026Board Meeting Outcome for Appointment Of Mr. Preetmohinder Singh Bedi (DIN: 11452004) As Additional Independent
Director Of The CompanyJan 01, 2026
Jan 01, 2026Announcement under Regulation 30 (LODR)-Change in ManagementJan 01, 2026
Jan 01, 2026Closure of Trading WindowDec 26, 2025
Dec 26, 2025Intimation Of Change In Name Of Managing Director Of The CompanyDec 01, 2025
Dec 01, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 22, 2025
Nov 22, 2025Unaudited Financial Results For The Quarter And Half Year Ended 30-09-2025Nov 13, 2025
Nov 13, 2025Board Meeting Outcome for To Consider And Approve The Financial Results For The Quarter And Half Year Ended 30-09-2025Nov 13, 2025
Nov 13, 2025Successful Completion Of The EU-GMP Audit At Its Amritsar General And Beta-Lactam UnitsNov 06, 2025
Nov 06, 2025Board Meeting Intimation for Consideration And Approval Of Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended On 30Th September 2025.Nov 05, 2025
Nov 05, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 11, 2025
Oct 11, 2025Closure of Trading WindowSep 27, 2025
Sep 27, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 11, 2025
Sep 11, 2025Regularization And Reappointment Of Directors At AGMSep 10, 2025
Sep 10, 2025Appointment Of Secretarial Auditors Of The CompanySep 09, 2025
Sep 09, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMSep 09, 2025
Sep 09, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 22, 2025
Aug 22, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 22, 2025
Aug 22, 2025Kwality Pharma Receives Product Registration For Bleomycin 15 IU In Mexico For Sale And Distribution.Aug 18, 2025
Aug 18, 2025Notice Of 42Nd AGM Of The Company Scheduled To Be Held On 09Th September 2025Aug 16, 2025
Aug 16, 2025Mutual Fund Holdings
| Funding House | Current Holding % | 1M Change | 1M Change % | 3M Change % | Last 6M Trend |
|---|---|---|---|---|---|
 Bandhan BSE Healthcare Index Fund Direct-Growth | 0.05% | 0 | 0.00% | 0.00% |
Technical Indicators
RSI(14)
Neutral 78.92
ATR(14)
Less Volatile 118.21
STOCH(9,6)
Overbought 81.79
STOCH RSI(14)
Oversold 0.00
MACD(12,26)
Bearish 0.00
ADX(14)
Weak Trend 0.00
UO(9)
Bullish 0.00
ROC(12)
Uptrend And Accelerating 23.38
WillR(14)
Overbought -11.94
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
